Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01726517
First received: November 10, 2012
Last updated: November 7, 2014
Last verified: November 2014
Results First Received: November 7, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Chronic Hepatitis C Virus
Interventions: Drug: LDV/SOF
Drug: RBV

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were enrolled at 1 study site in the United States. The first participant was screened on 22 October 2012. The last participant observation was on 13 January 2014.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
116 participants were screened.

Reporting Groups
  Description
LDV/SOF 8 Weeks (TN) Treatment-naive (TN) participants were randomized to receive ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg for 8 weeks.
LDV/SOF+RBV 8 Weeks (TN) Treatment-naive participants were randomized to receive LDV 90 mg/SOF 400 mg plus weight-based ribavirin (RBV) (1000-1200 mg) for 8 weeks.
LDV/SOF 12 Weeks (TN) Treatment-naive participants were randomized to receive LDV 90 mg/SOF 400 mg for 12 weeks.
LDV/SOF 12 Weeks (TE) Treatment-experienced (TE) participants (had virologic failure following prior therapy with a protease-inhibitor [PI]+pegylated interferon [PEG]+RBV regimen) were randomized to receive LDV 90 mg/SOF 400 mg for 12 weeks.
LDV/SOF+RBV 12 Weeks (TE) Treatment-experienced participants (had virologic failure following prior therapy with a PI+PEG+RBV regimen) were randomized to receive LDV 90 mg/SOF 400 mg plus weight-based RBV (1000-1200 mg) for 12 weeks.

Participant Flow:   Overall Study
    LDV/SOF 8 Weeks (TN)     LDV/SOF+RBV 8 Weeks (TN)     LDV/SOF 12 Weeks (TN)     LDV/SOF 12 Weeks (TE)     LDV/SOF+RBV 12 Weeks (TE)  
STARTED     20     21     19     19     21  
COMPLETED     20     21     18     19     21  
NOT COMPLETED     0     0     1     0     0  
Withdrawal by Subject                 0                 0                 1                 0                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Safety Analysis Set: participants received at least 1 dose of study drug

Reporting Groups
  Description
LDV/SOF 8 Weeks (TN) Treatment-naive participants were randomized to receive LDV 90 mg/SOF 400 mg for 8 weeks.
LDV/SOF+RBV 8 Weeks (TN) Treatment-naive participants were randomized to receive LDV 90 mg/SOF 400 mg plus weight-based RBV (1000-1200 mg) for 8 weeks.
LDV/SOF 12 Weeks (TN) Treatment-naive participants were randomized to receive LDV 90 mg/SOF 400 mg for 12 weeks.
LDV/SOF 12 Weeks (TE) Treatment-experienced participants (had virologic failure following prior therapy with a PI+PEG+RBV regimen) were randomized to receive LDV 90 mg/SOF 400 mg for 12 weeks.
LDV/SOF+RBV 12 Weeks (TE) Treatment-experienced participants (had virologic failure following prior therapy with a PI+PEG+RBV regimen) were randomized to receive LDV 90 mg/SOF 400 mg plus weight-based RBV (1000-1200 mg) for 12 weeks.
Total Total of all reporting groups

Baseline Measures
    LDV/SOF 8 Weeks (TN)     LDV/SOF+RBV 8 Weeks (TN)     LDV/SOF 12 Weeks (TN)     LDV/SOF 12 Weeks (TE)     LDV/SOF+RBV 12 Weeks (TE)     Total  
Number of Participants  
[units: participants]
  20     21     19     19     21     100  
Age  
[units: years]
Mean ± Standard Deviation
  48  ± 10.7     50  ± 11.1     46  ± 11.6     54  ± 6.6     52  ± 9.8     50  ± 10.4  
Gender  
[units: participants]
           
Female     6     9     8     4     7     34  
Male     14     12     11     15     14     66  
Ethnicity (NIH/OMB)  
[units: participants]
           
Hispanic or Latino     3     12     9     6     10     40  
Not Hispanic or Latino     17     9     10     13     11     60  
Unknown or Not Reported     0     0     0     0     0     0  
Race (NIH/OMB)  
[units: participants]
           
American Indian or Alaska Native     0     0     0     1     0     1  
Asian     1     0     1     0     0     2  
Native Hawaiian or Other Pacific Islander     0     0     0     0     0     0  
Black or African American     4     0     1     2     2     9  
White     15     21     17     16     19     88  
More than one race     0     0     0     0     0     0  
Unknown or Not Reported     0     0     0     0     0     0  
Hepatitis C Virus (HCV) Genotype [1]
[units: participants]
           
1a     17     19     17     18     16     87  
1b     3     2     2     1     5     13  
IL28b Status [2]
[units: participants]
           
CC     4     7     1     2     1     15  
CT     12     11     14     13     11     61  
TT     4     3     4     4     9     24  
HCV RNA (log10 IU/mL)  
[units: log10┬áIU/mL]
Mean ± Standard Deviation
  6.1  ± 0.82     6.0  ± 0.84     6.1  ± 0.79     6.3  ± 0.49     6.2  ± 0.42     6.1  ± 0.69  
HCV RNA Category  
[units: participants]
           
< 800,000 IU/mL     9     7     7     4     5     32  
≥ 800,000 IU/mL     11     14     12     15     16     68  
Prior HCV Treatment and Response [3]
[units: participants]
           
Non-responder to PI boceprevir     0     0     0     9     9     18  
Relapse/Breakthrough to PI boceprevir     0     0     0     2     2     4  
Non-responder to PI telaprevir     0     0     0     3     6     9  
Relapse/Breakthrough to PI telaprevir     0     0     0     5     4     9  
Cirrhosis  
[units: participants]
           
No     20     21     19     8     10     78  
Yes     0     0     0     11     11     22  
[1] There are variations within HCV genotype 1 which are distinct enough to be referred to as genotypes 1a or 1b.
[2] CC, CT, and TT alleles are different forms of the IL28b gene.
[3] Prior HCV treatment and response was only collected for treatment-experienced participants in the LDV/SOF 12 Weeks (TE) and LDV/SOF+RBV 12 Weeks (TE) groups.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)   [ Time Frame: Posttreatment Week 12 ]

2.  Primary:   Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)   [ Time Frame: Baseline to Week 12 ]

3.  Secondary:   Percentage of Participants With SVR at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR24)   [ Time Frame: Posttreatment Weeks 2, 4, 8, and 24 ]

4.  Secondary:   Percentage of Participants Experiencing Viral Breakthrough or Viral Relapse   [ Time Frame: Baseline to Posttreatment Week 24 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Clinical Trial Disclosures
Organization: Gilead Sciences, Inc.
e-mail: ClinicalTrialDisclosures@gilead.com


No publications provided by Gilead Sciences

Publications automatically indexed to this study:

Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT01726517     History of Changes
Other Study ID Numbers: GS-US-337-0118
Study First Received: November 10, 2012
Results First Received: November 7, 2014
Last Updated: November 7, 2014
Health Authority: United States: Food and Drug Administration